Overview

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

Status:
Completed

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the safety, tolerability and plasma pharmacokinetic (PK) profile of TAK-915 when administered as single and multiple oral suspension doses at escalating dose levels in healthy participants, including elderly participants.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Midazolam